Kole Christo, Charalampakis Nikolaos, Tsakatikas Sergios, Frountzas Maximos, Apostolou Konstantinos, Schizas Dimitrios
First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, 115 27, Greece.
Department of Medical Oncology, Metaxa Cancer Hospital, Athens, 185 37, Greece.
Cancer Manag Res. 2022 Mar 8;14:1043-1061. doi: 10.2147/CMAR.S267260. eCollection 2022.
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and fourth most common cause of death in developed countries. Despite improved survival rates after resection combined with adjuvant chemotherapy or neoadjuvant chemotherapy, recurrence still occurs in a high percentage of patients within the first 2 years after resection. Immunotherapy aims to improve antitumor immune responses and reduce toxicity providing a more specific, targeted therapy compared to chemotherapy and has been proved an efficient therapeutic tool for many solid tumors. In this work, we present the latest advances in PDAC treatment using a combination of immunotherapy with other interventions such as chemotherapy and/or radiation both at neoadjuvant and adjuvant setting. Moreover, we outline the role of the tumor microenvironment as a key barrier to immunotherapy efficacy and examine how immunotherapy biomarkers may be used to detect immunotherapy's response.
胰腺导管腺癌（PDAC）是最常见的胰腺癌类型，在发达国家是第四大常见死因。尽管手术切除联合辅助化疗或新辅助化疗后生存率有所提高，但仍有很高比例的患者在切除后的头两年内复发。免疫疗法旨在改善抗肿瘤免疫反应并降低毒性，与化疗相比提供了一种更具特异性、靶向性的治疗方法，并且已被证明是治疗许多实体瘤的有效治疗工具。在这项工作中，我们展示了在新辅助和辅助治疗阶段将免疫疗法与化疗和/或放疗等其他干预措施相结合用于PDAC治疗的最新进展。此外，我们概述了肿瘤微环境作为免疫疗法疗效的关键障碍所起的作用，并研究了免疫疗法生物标志物如何用于检测免疫疗法的反应。
